drugset / Trial / NCT05400746
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK
Timeline
- Start
- 2022-11-02
- Primary completion
- 2023-10-19
- Completion
- 2023-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pfs48/45 | Vaccine | 10 ug | Intramuscular |
| Subject | Pfs48/45 | Vaccine | 50 ug | Intramuscular |
| Background | Matrix-M1 Adjuvant | Other / unclassified | 50 ug | Intramuscular |